DXM Abuse Prevention Act of 2017

- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects - S.1113, "Personal Care Products Safety Act", regarding all provisions - HR 2790, "Humane Cosmetics Act", regarding all provisions - HR 3271, "Protecting Access to Diabetes Supplies Act", regarding all provisions - Issues regarding medical device repeal - Issues regarding NIH Funding - HR 2164, "Medical Device Safety Act", regarding all provisions - Issues related to 340B - Issues related to HIV vaccines - S. 2852, "Pandemic & All Hazards Preparedness and Advancing Innovations Act of 2018", regarding all provisions. - Issues related to reauthorization of the Pandemic All-Hazards Preparedness Act programs. (House version) - HR 5492, "MOTHER Act of 2018", regarding all provisions. - Issues related to access to essential surgery - Issues related to contact lens safety - HR 6, "SUPPORT for Patients and Communities Act", regarding all provisions. - S. 2315, "Over-the-Counter Drug Safety, Innovation, and Reform Act", regarding all provisions. - HR 5333 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018", regarding all provisions. - Issues related to antimicrobial resistance - Issues related to regulations on medication product packaging - H.R. 6294, " Re-Valuing Anti-Microbial Products Act of 2018", regarding all provisions

Client expense: $1,980,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA), White House Office

Issues related to the sale of medicines that contain dextromethorphan, including H.R. 1271, the DXM Abuse Prevention Act of 2017.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of Public Law 114-198 pharmacy provisions; Implementation of Public Law 114-255 pharmacy provisions; H.R. 1854/S. 778, Prescription Drug Monitoring Act of 2017; S 892 / H.R. 4408, Opioid Addiction Prevention Act of 2017; HR 3528 / S.2460, Every Prescription Conveyed Securely Act; H.R. 3545, Overdose Prevention and Patient Safety Act; S. 1850, Protecting Jessica Grubbs Legacy Act; H.R. 1271, DXM Abuse Prevention Act of 2017; H.R. 1375, Prescriber Support Act of 2017; S. 523, Budgeting for Opioid Addiction Treatment Act; S. 581 / H.R. 5009, Jessies Law; S 1079, Protecting Americans from Dangerous Opioids Act; H.R. 4236, MONITOR Act of 2017; H.R. 3991, Expanded Access to Opioid Abuse Treatment Act of 2017; H.R. 4275, Empowering Pharmacists in the Fight Against Opioid Abuse Act; H.R. 5219, Opioid Prescription Verification Act of 2018; H.R. 5676, SENIOR Communities Protection Act of 2018; H.R. 5773, PASS Act of 2018; Draft legislation, Medicare Care Coordination Improvement Act of 2017; Draft legislation, Pain Care Coordination Act of 2018; S. 2456/H.R. 5311, CARA 2.0 Act of 2018; H.R. 5687, SOUND Disposal and Packaging Act; H.R. 5202, Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018; H.R. 5812, CONNECTIONS Act; H.R. 5801, Medicaid PARTNERSHIP Act; H.R. 6, SUPPORT for Patients and Communities Act; H.R. 5808, Medicaid Pharmaceutical Home Act of 2018; H.R. 5675, To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries; S. 2680, Opioid Crisis Response Act of 2018; S. 2645 / H.R. 5628, Access to Increased Drug Disposal Act of 2018; H.R. 6600 / S. 3282, the DEA Order Clearinghouse Act of 2018; H.R. 6688, ALERT Act of 2018

Dextromethorphan H.R. 1271, the "DXM Abuse Prevention Act" (DAP) - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections. Tableting and Encapsulating Machine Regulation Act of 2018, no bill number. Gives the Drug Enforcement Agency additional authority to regulate tableting and encapsulating manufacturing machines. FDA Packaging and Disposal, no bill number. Directs FDA to work with manufacturers to establish programs for efficient return or destruction of unused Schedule II drugs, with an emphasis on opioids. These methods could include mail-back pouches to secure facilities for incineration, or methods to immediately inactivate/render unattractive unused drugs. H.R. 5628/S. 2645 Access to Increased Drug Disposal Act of 2018. Establishes a demonstration program under which the Drug Enforcement Administration provides grants and technical assistance to certain States to enable those States to increase participation in drug take-back programs. H.R.6 - SUPPORT for Patients and Communities Act. This bill makes several changes to state Medicaid programs to address opioid and substance use disorders. The bill also alters Medicare requirements to address opioid use. Additionally, the bill temporarily eliminates the enhanced federal matching rate for Medicaid expenditures regarding specified medical services provided by certain managed care organizations.

Client expense: $198,000 · Firm income: Not reported

- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects - S.1113, "Personal Care Products Safety Act", regarding all provisions - HR 2790, "Humane Cosmetics Act", regarding all provisions - Issues related to over the counter medicine regulatory reform - HR 3271, "Protecting Access to Diabetes Supplies Act", regarding all provisions - Issues regarding medical device repeal - Issues regarding NIH Funding - HR 2164, "Medical Device Safety Act", regarding all provisions - Issues related to 340B - Issues related to HIV vaccines - S. 2852, "Pandemic & All Hazards Preparedness and Advancing Innovations Act of 2018", regarding all provisions. - Issues related to reauthorization of the Pandemic All-Hazards Preparedness Act programs. (House version) - HR 5492, "MOTHER Act of 2018", regarding all provisions. - Issues related to access to essential surgery - Issues related to contact lens safety

Implementation of Public Law 114-198 pharmacy provisions; Implementation of Public Law 114-255 pharmacy provisions; H.R. 1854/S. 778, Prescription Drug Monitoring Act of 2017; S 892 / H.R. 4408, Opioid Addiction Prevention Act of 2017; HR 3528 / S.2460, Every Prescription Conveyed Securely Act; H.R. 3545, Overdose Prevention and Patient Safety Act; S. 1850, Protecting Jessica Grubbs Legacy Act; H.R. 1271, DXM Abuse Prevention Act of 2017; H.R. 1375, Prescriber Support Act of 2017; S. 523, Budgeting for Opioid Addiction Treatment Act; S. 581 / H.R. 5009, Jessies Law; S 1079, Protecting Americans from Dangerous Opioids Act; H.R. 4236, MONITOR Act of 2017; H.R. 3991, Expanded Access to Opioid Abuse Treatment Act of 2017; H.R. 4275, Empowering Pharmacists in the Fight Against Opioid Abuse Act; H.R. 5219, Opioid Prescription Verification Act of 2018; H.R. 5676, SENIOR Communities Protection Act of 2018; H.R. 5773, PASS Act of 2018; Draft legislation, Medicare Care Coordination Improvement Act of 2017; Draft legislation, Pain Care Coordination Act of 2018; S. 2456/H.R. 5311, CARA 2.0 Act of 2018; H.R. 5687, SOUND Disposal and Packaging Act; H.R. 5202, Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018; H.R. 5812, CONNECTIONS Act; H.R. 5801, Medicaid PARTNERSHIP Act; H.R. 6, SUPPORT for Patients and Communities Act; H.R. 5808, Medicaid Pharmaceutical Home Act of 2018; H.R. 5675, To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries; S. 2680, Opioid Crisis Response Act of 2018; S. 2645 / H.R. 5628, Access to Increased Drug Disposal Act of 2018;

Client expense: $320,000 · Firm income: Not reported

Dextromethorphan H.R. 1271, the "DXM Abuse Prevention Act" (DAP) - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections. Tableting and Encapsulating Machine Regulation Act of 2018, no bill number. Gives the Drug Enforcement Agency additional authority to regulate tableting and encapsulating manufacturing machines. FDA Packaging and Disposal, no bill number. Directs FDA to work with manufacturers to establish programs for efficient return or destruction of unused Schedule II drugs, with an emphasis on opioids. These methods could include mail-back pouches to secure facilities for incineration, or methods to immediately inactivate/render unattractive unused drugs. H.R. 5628/S. 2645 Access to Increased Drug Disposal Act of 2018. Establishes a demonstration program under which the Drug Enforcement Administration provides grants and technical assistance to certain States to enable those States to increase participation in drug take-back programs.

Client expense: $255,000 · Firm income: Not reported

Issues related to the sale of medicines that contain dextromethorphan, including H.R. 1271, the DXM Abuse Prevention Act of 2017.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - Issues related to blood glucose meters. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects - S.1113, "Personal Care Products Safety Act", regarding all provisions - HR 2790, "Humane Cosmetics Act", regarding all provisions - Issues related to over the counter medicine regulatory reform - HR 3271, "Protecting Access to Diabetes Supplies Act", regarding all provisions - Issues regarding medical device repeal - Issues regarding NIH Funding - HR 2164, "Medical Device Safety Act", regarding all provisions - Issues related to 340B - Issues related to HIV vaccines - Issues related to reauthorization of the Pandemic All-Hazards Preparedness Act programs. - HR 5492, "MOTHER Act of 2018", regarding all provisions.

HR 1271 DXM Abuse Prevention Act of 2017 HR 1375 Prescriber Support Act of 2017 HR 1575 Addiction Recovery through Family Health Accounts Act S 523 Budgeting for Opioid Addiction Treatment Act S 581 To include information concerning a patient's opioid addiction in certain medical records. HR 1854/S 778 Prescription Drug Monitoring Act of 2017 HR 3991 allow certain pharmacists to dispense narcotic drugs for maintenance or detoxification treatment HR 3692 amends the Controlled Substances Act to provide for additional flexibility with respect to medication-assisted treatment for opioid use disorders

Client expense: $34,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the sale of medicines that contain dextromethorphan, including H.R. 1271, the DXM Abuse Prevention Act of 2017.

Client expense: Not reported · Firm income: $50,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Implementation of Public Law 114-198 pharmacy provisions; Implementation of Public Law 114-255 pharmacy provisions; H.R. 1854/S. 778, Prescription Drug Monitoring Act of 2017; S 892 / H.R. 4408, Opioid Addiction Prevention Act of 2017; HR 3528 / S.2460, Every Prescription Conveyed Securely Act; H.R. 3545, Overdose Prevention and Patient Safety Act; S. 1850, Protecting Jessica Grubbs Legacy Act; H.R. 1271, DXM Abuse Prevention Act of 2017; H.R. 1375, Prescriber Support Act of 2017; S. 523, Budgeting for Opioid Addiction Treatment Act; S. 581, Jessies Law; S 1079, Protecting Americans from Dangerous Opioids Act; H.R. 4236, MONITOR Act of 2017; H.R. 3991, Expanded Access to Opioid Abuse Treatment Act of 2017; H.R. 4275, Empowering Pharmacists in the Fight Against Opioid Abuse Act H.R. 5219, Opioid Prescription Verification Act of 2018 Draft legislation on suspension of payments for pharmacies suspected of fraud in Medicare Part D Draft legislation, Medicare Care Coordination Improvement Act of 2017 Draft legislation, Pain Care Coordination Act of 2018 S. 2456/H.R. 5311, CARA 2.0 Act of 2018 Discussion Draft of H.R. __, FDA Packaging and Disposal H.R. 5202, Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018

Client expense: $400,000 · Firm income: Not reported

Dextromethorphan H.R. 1271, the "DXM Abuse Prevention Act" (DAP) - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections. Tableting and Encapsulating Machine Regulation Act of 2018, no bill number. Gives the Drug Enforcement Agency additional authority to regulate tableting and encapsulating manufacturing machines. FDA Packaging and Disposal, no bill number. Directs FDA to work with manufacturers to establish programs for efficient return or destruction of unused Schedule II drugs, with an emphasis on opioids. These methods could include mail-back pouches to secure facilities for incineration, or methods to immediately inactivate/render unattractive unused drugs. Access to Increased Drug Disposal Act of 2018, no bill number. Establishes a demonstration program under which the Drug Enforcement Administration provides grants and technical assistance to certain States to enable those States to increase participation in drug take-back programs.

Client expense: $192,000 · Firm income: Not reported

H.R. 1038/S. 413 - Improving Transparency and Accuracy in Medicare Part D Spending Act H.R. 1271 - DXM Abuse Prevention Act of 2017 H.R.592/S. 109 - Pharmacy and Medically Underserved Areas Enhancement Act H.R. 1038/S. 413 - Improving Transparency and Accuracy in Medicare Part D Spending Act H.R. 1316 - Prescription Drug Price Transparency Act H.R. 592/S. 109 - Pharmacy and Medically Underserved Areas Enhancement Act H.R. 623 - Fairness to Pet Owners Act

Client expense: $170,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

H.R.1628 - American Health Care Act of 2017 Draft Health Care-related Amendments to Senate Consideration of H.R. 1628 to provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017 H.R. 1038/S. 413 - Improving Transparency and Accuracy in Medicare Part D Spending Act H.R. 1271 - DXM Abuse Prevention Act of 2017 H.R.592/S. 109 - Pharmacy and Medically Underserved Areas Enhancement Act H.R. 1313 - The Preserving Employee Wellness Programs Act H.R. 3919/S. 1908 - Commonsense Reporting Act of 2017 H.R. 3798 - Save American Workers Act of 2017 Cadillac Tax delay letter HIT delay FSA OTC tax rules

Client expense: $170,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - Issues related to blood glucose meters. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects - S.1113, "Personal Care Products Safety Act", regarding all provisions - HR 2790, "Humane Cosmetics Act", regarding all provisions - Issues related to over the counter medicine regulatory reform - HR 3271, "Protecting Access to Diabetes Supplies Act", regarding all provisions - Issues regarding medical device repeal - Issues regarding NIH Funding - HR 2164, "Medical Device Safety Act", regarding all provisions - Issues related to 340B - Issues related to HIV vaccines

Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications H.R. 1271 - DXM Abuse Prevention Act of 2017

Client expense: Not reported · Firm income: $40,000

Dextromethorphan H.R. 1271, the "DXM Abuse Prevention Act" (DAP) - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections.

Client expense: $228,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of

Implementation of Public Law 114-198 pharmacy provisions; Implementation of Public Law 114-255 pharmacy provisions; H.R. 1854/S. 778, Prescription Drug Monitoring Act of 2017; S 892, Opioid Addiction Prevention Act of 2017; HR 3528, Every Prescription Conveyed Securely Act; H.R. 3545, Overdose Prevention and Patient Safety Act; S. 1850, Protecting Jessica Grubbs Legacy Act; H.R. 1271, DXM Abuse Prevention Act of 2017; H.R. 1375, Prescriber Support Act of 2017; S. 523, Budgeting for Opioid Addiction Treatment Act; S. 581, Jessies Law; S 1079, Protecting Americans from Dangerous Opioids Act; H.R. 4236, MONITOR Act of 2017; H.R. 3991, Expanded Access to Opioid Abuse Treatment Act of 2017; H.R. 4275, Empowering Pharmacists in the Fight Against Opioid Abuse Act

Client expense: $480,000 · Firm income: Not reported

Issues related to the sale of medicines that contain dextromethorphan, including H.R. 1271, the DXM Abuse Prevention Act of 2017.

Client expense: Not reported · Firm income: $50,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

HR 1271 DXM Abuse Prevention Act of 2017 HR 1375 Prescriber Support Act of 2017 HR 1575 Addiction Recovery through Family Health Accounts Act S 523 Budgeting for Opioid Addiction Treatment Act S 581 To include information concerning a patient's opioid addiction in certain medical records. HR 1854/S 778 Prescription Drug Monitoring Act of 2017

Client expense: $34,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of Public Law 114-198 pharmacy provisions; Implementation of Public Law 114-255 pharmacy provisions; H.R. 1854/S. 778, Prescription Drug Monitoring Act of 2017; S 892, Opioid Addiction Prevention Act of 2017; HR 3528, Every Prescription Conveyed Securely Act; H.R. 3545, Overdose Prevention and Patient Safety Act; S. 1850, Protecting Jessica Grubbs Legacy Act; H.R. 1271, DXM Abuse Prevention Act of 2017; H.R. 1375, Prescriber Support Act of 2017; S. 523, Budgeting for Opioid Addiction Treatment Act; S. 581, Jessies Law; S 1079, Protecting Americans from Dangerous Opioids Act;

Client expense: $380,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), Office of Personnel Management (OPM), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Treasury, Dept of, White House Office

H.R.1628 - American Health Care Act of 2017 Draft Health Care-related Amendments to Senate Consideration of H.R. 1628 to provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017 H.R. 1038/S. 413 - Improving Transparency and Accuracy in Medicare Part D Spending Act H.R. 1271 - DXM Abuse Prevention Act of 2017 H.R.592/S. 109 - Pharmacy and Medically Underserved Areas Enhancement Act H.R. 1313 - The Preserving Employee Wellness Programs Act H.R. 3919/S. 1908 - Commonsense Reporting Act of 2017 H.R. 3798 - Save American Workers Act of 2017

Client expense: $210,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1038/S. 413 - Improving Transparency and Accuracy in Medicare Part D Spending Act H.R. 1271 - DXM Abuse Prevention Act of 2017 H.R.592/S. 109 - Pharmacy and Medically Underserved Areas Enhancement Act H.R. 1038/S. 413 - Improving Transparency and Accuracy in Medicare Part D Spending Act H.R. 1316 - Prescription Drug Price Transparency Act H.R. 592/S. 109 - Pharmacy and Medically Underserved Areas Enhancement Act H.R. 623 - Fairness to Pet Owners Act

Client expense: $210,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - Issues related to blood glucose meters. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects - S.113, "Personal Care Products Safety Act", regarding all provisions - HR 2790, "Humane Cosmetics Act", regarding all provisions - Issues related to over the counter medicine regulatory reform - HR 3271, "Protecting Access to Diabetes Supplies Act", regarding all provisions - Issues regarding medical device repeal - Issues regarding NIH Funding - HR 2164, "Medical Device Safety Act", regarding all provisions - Issues related to 340B

Client expense: $810,000 · Firm income: Not reported

Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications H.R. 1271 - DXM Abuse Prevention Act of 2017

Client expense: Not reported · Firm income: $40,000

Issues related to the sale of medicines that contain dextromethorphan, including H.R. 1271, the DXM Abuse Prevention Act of 2017.

Client expense: Not reported · Firm income: $50,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

HR 1271 DXM Abuse Prevention Act of 2017 HR 1375 Prescriber Support Act of 2017 HR 1575 Addiction Recovery through Family Health Accounts Act S 523 Budgeting for Opioid Addiction Treatment Act S 581 To include information concerning a patient's opioid addiction in certain medical records. HR 1854/S 778 Prescription Drug Monitoring Act of 2017

Client expense: $34,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Dextromethorphan H.R. 1271, the "DXM Abuse Prevention Act" (DAP) - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections.

Client expense: $176,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of

H.R. 2810, National Defense Authorization Act for Fiscal Year 2018, pilot program for TRICARE pharmacy benefit. H.R. 1628, American Health Care Act of 2017. S. ____, Better Care Reconciliation Act of 2017. H.R. 1271, DXM Abuse Prevention Act of 2017. H.R. 1854/S. 778, Prescription Drug Monitoring Act of 2017. S. 892, A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes. H.R. 1245/S. 469, Affordable and Safe Prescription Drug Importation Act. H.R. 749, Lower Drug Costs through Competition Act. S. 297, Increasing Competition in Pharmaceuticals Act. H.R. 2051, Fast Generics Act of 2017. Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148), Medicare Access and CHIP Reauthorization Act (P.L. 114-10), Comprehensive Addiction and Recovery Act (P.L. 114-198), National Defense Authorization Act for Fiscal Year 2017 (P.L. 114-328), 21st Century Cures Act (P.L. 114-255), Ensuring Patient Access and Effective Drug Enforcement Act of 2016 (P.L. 114-145).

Client expense: $190,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.1628 - American Health Care Act of 2017, Draft Senate Amendment to H.R. 1628 H.R. 1038/S. 413 - Improving Transparency and Accuracy in Medicare Part D Spending Act H.R. 1271 - DXM Abuse Prevention Act of 2017 H.R.592/S. 109 - Pharmacy and Medically Underserved Areas Enhancement Act H.R. 1313 - The Preserving Employee Wellness Programs Act

Client expense: $350,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1038/S. 413 - Improving Transparency and Accuracy in Medicare Part D Spending Act H.R. 1271 - DXM Abuse Prevention Act of 2017 H.R.592/S. 109 - Pharmacy and Medically Underserved Areas Enhancement Act

Client expense: $350,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications H.R. 1271 - DXM Abuse Prevention Act of 2017

Client expense: Not reported · Firm income: $40,000

- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - Issues related to blood glucose meters. - Issues related to 21st Century Cures Act. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2430, FDA Reauthorization Act - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects

Client expense: $1,290,000 · Firm income: Not reported

Issues related to the sale of medicines that contain dextromethorphan, including H.R. 1271, the DXM Abuse Prevention Act of 2017.

Client expense: Not reported · Firm income: $50,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

HR 1271 DXM Abuse Prevention Act of 2017 HR 1375 Prescriber Support Act of 2017 HR 1575 Addiction Recovery through Family Health Accounts Act S 523 Budgeting for Opioid Addiction Treatment Act S 581 To include information concerning a patient's opioid addiction in certain medical records. HR 1854/S 778 Prescription Drug Monitoring Act of 2017

Client expense: $30,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Dextromethorphan H.R. 1271, the "DXM Abuse Prevention Act" (DAP) - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections.

Client expense: $215,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of

S. 64: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 92: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 204: Trickett Wendler Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness S. 297: Increasing Competition in Pharmaceuticals Act - Provisions related to generic drug approvals S. 456: RACE for Children Act - Provisions related to pediatric studies S. 469: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 771: Improving Access to Affordable Prescription Drugs Act - Provisions related to drug pricing HR 394/S 85 - Restoring Access to Medication Act of 2017Monograph Reform legislation H.R. 749: Lower Drug Costs Through Competition Act - Provisions related to generic drug approvals H.R. 820: Childhood Cancer STAR Act - Provisions related to expanded access and other policy issues H.R. 878: Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 1108: Recall Unsafe Drugs Act of 2017 - Provisions related to drug recalls H.R. 1231: RACE for Children Act - Provisions related to pediatric studies H.R. 1245: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation HR 1271 - DXM Abuse Prevention Act of 2017 H.R. 1480: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation H.R. 1628: American Health Care Act of 2017 - Provisions related to the biopharmaceutical industry including repeal of brand pharmaceutical manufacturer fee and individual and employer mandates, insurance affordability provisions, and Medicaid reforms H.R. 1776: Improving Access to Affordable Prescription Drugs Act - Provisions related to drug pricing Repeal of the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148) and related policy issues including the pharmaceutical fee Prescription Drug User Fee Act (PDUFA) reauthorization Biologics User Fee Act (BsUFA) reauthorization Biopharmaceutical innovation policy issues Reforms to the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) Drug cost and pricing policy issues Transparency policy issues Drug importation and counterfeiting policy issues Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse Expanded access policy issues Expedited drug approval policy issues Generic drug approval process policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues Vaccines policy issues Limited distribution systems in the pharmaceutical supply chain policy issues FDA modernization policy issues 340B drug discount program policy issues Orphan Drug Act policy issues 21st Century Cures Act (Public Law 114-255) - Provisions related to biopharmaceutical discovery, development, delivery, and transparency Senate HELP Committee Innovation Agenda - Provisions related to biopharmaceutical discovery and development and FDA policy Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues Food and Drug Administration Final Rule on Intended Use (82 Fed. Reg. 2193 (Jan. 9, 2017)) Biologics Price Competition and Innovation Act (BPCIA) implementation issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Biomarker policy issues Drug compounding policy issues Clinical trial policy issues Cancer drug vial size policy issues Antibiotic development policy issues Nomination and Confirmation of Tom Price as HHS Secretary Nomination and Confirmation of Scott Gottlieb as FDA Commissioner

H.R. 1271, DXM Abuse Prevention Act of 2017. H.R. 1854/S. 778, Prescription Drug Monitoring Act of 2017. S. 892, A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes. H.R. 1245/S. 469, Affordable and Safe Prescription Drug Importation Act. H.R. 749, Lower Drug Costs through Competition Act. S. 297, Increasing Competition in Pharmaceuticals Act. H.R. 2051, Fast Generics Act of 2017. Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148), Medicare Access and CHIP Reauthorization Act (P.L. 114-10), Comprehensive Addiction and Recovery Act (P.L. 114-198), National Defense Authorization Act for Fiscal Year 2017 (P.L. 114-328), 21st Century Cures Act (P.L. 114-255), Ensuring Patient Access and Effective Drug Enforcement Act of 2016 (P.L. 114-145).

Client expense: $570,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues related to user fees. - Issues regarding drug pricing. - Issues related to diagnostic reform. - Issues related to blood glucose meters. - Issues related to 21st Century Cures Act. - Issues related to CDC guidelines related to surgical site infections. - Issues related to FDA inspections legislation (not yet introduced)

Client expense: $1,060,000 · Firm income: Not reported

Issues related to the sale of medicines that contain dextromethorphan, including H.R. 1271, the DXM Abuse Prevention Act of 2017.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications H.R. 1271 - DXM Abuse Prevention Act of 2017

Client expense: Not reported · Firm income: $40,000

Dextromethorphan H.R. 1271, the "DXM Abuse Prevention Act" (DAP) - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections.

Client expense: $252,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of

HR 1271 DXM Abuse Prevention Act of 2017 HR 1375 Prescriber Support Act of 2017 HR 1575 Addiction Recovery through Family Health Accounts Act S 523 Budgeting for Opioid Addiction Treatment Act S 581 To include information concerning a patient's opioid addiction in certain medical records.

Client expense: $30,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE